Literature DB >> 28769333

FIBRIN AND FIBRINOGEN DEGRADATION PRODUCTS IN MALIGNANCY.

Ramji Rai1, Brig Skbasu2, M P Jaiprakash3.   

Abstract

Sixty four patients of cancer, comprising of 39 leukaemia, 8 lymphomas and 17 cases of solid tumours were included in this study. Quantitative estimation of FDP, fibrinogen and platelets were done in all. Elevated levels of FDP (≥ 10 µgm/mL) were found in 29 patients. These patients were further categorised as decompensated, overcompensated and compensated intravascular coagulation and fibrinolytic syndrome on the basis of platelet counts and fibrinogen levels.

Entities:  

Keywords:  Disseminated intravascular coagulation; Fibrin fibrinogen degradation product; Leukemia

Year:  2017        PMID: 28769333      PMCID: PMC5530261          DOI: 10.1016/S0377-1237(17)30831-6

Source DB:  PubMed          Journal:  Med J Armed Forces India        ISSN: 0377-1237


  8 in total

1.  [Rapid physiological coagulation method in determination of fibrinogen].

Authors:  A CLAUSS
Journal:  Acta Haematol       Date:  1957-04       Impact factor: 2.195

2.  Cancer procoagulant A: a factor X activating procoagulant from malignant tissue.

Authors:  S G Gordon; J J Franks; B Lewis
Journal:  Thromb Res       Date:  1975-02       Impact factor: 3.944

3.  Evaluation of patients with increased fibrinolytic split products (FSP) in their serum.

Authors:  H A Cooper; E J Bowie; C A Owen
Journal:  Mayo Clin Proc       Date:  1974-09       Impact factor: 7.616

4.  The Thrombo-Wellcotest as a screening test for disseminated intravascular coagulation.

Authors:  L Ellman; A Carvalho; R W Colman
Journal:  N Engl J Med       Date:  1973-03-22       Impact factor: 91.245

5.  Cancer cell procoagulant activity: evaluation by an amidolytic assay.

Authors:  M Colucci; L Curatolo; M B Donati; N Semeraro
Journal:  Thromb Res       Date:  1980 May 1-15       Impact factor: 3.944

6.  The significance of the fibrin/fibrinogen degradation product in serum of carcinoma patients with hematogenous metastasis.

Authors:  S Imaoka; Y Sasaki; T Iwanaga; T Terasawa
Journal:  Cancer       Date:  1986-10-01       Impact factor: 6.860

7.  Abnormalities of blood coagulation in patients with cancer. Fibrinopeptide A generation and tumor growth.

Authors:  F R Rickles; R L Edwards; C Barb; M Cronlund
Journal:  Cancer       Date:  1983-01-15       Impact factor: 6.860

8.  Hemostatic abnormalities in malignancy, a prospective study of one hundred eight patients. Part I. Coagulation studies.

Authors:  N C Sun; W M McAfee; G J Hum; J M Weiner
Journal:  Am J Clin Pathol       Date:  1979-01       Impact factor: 2.493

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.